I 
117TH CONGRESS 
2D SESSION 
H. R. 8877 
To direct the Secretary of Health and Human Services to evaluate the 
extent to which the substitution of interchangeable biological products 
may be impeded by differences between the system for determining a 
biological product to be interchangeable and the system for assigning 
therapeutic equivalence ratings to drugs, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 19, 2022 
Mrs. MILLER-MEEKS (for herself, Mr. MURPHY of North Carolina, Ms. 
BARRAGA´N, and Ms. KUSTER) introduced the following bill; which was re-
ferred to the Committee on Energy and Commerce 
A BILL 
To direct the Secretary of Health and Human Services to 
evaluate the extent to which the substitution of inter-
changeable biological products may be impeded by dif-
ferences between the system for determining a biological 
product to be interchangeable and the system for assign-
ing therapeutic equivalence ratings to drugs, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
VerDate Sep 11 2014 
22:05 Sep 26, 2022
Jkt 029200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H8877.IH
H8877
kjohnson on DSK79L0C42PROD with BILLS
2 
•HR 8877 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Biologics Competition 
2
Act of 2022’’. 
3
SEC. 2. STUDY ON CERTAIN IMPEDIMENTS TO THE SUBSTI-
4
TUTION OF INTERCHANGEABLE BIOLOGICAL 
5
PRODUCTS. 
6
Not later than 12 months after the date of enactment 
7
of this Act, the Secretary of Health and Human Services 
8
shall— 
9
(1) complete a study to evaluate the extent to 
10
which the substitution of interchangeable biological 
11
products licensed under section 351 of the Public 
12
Health Service Act (42 U.S.C. 262) may be impeded 
13
by differences between the system for determining a 
14
biological product to be interchangeable under sec-
15
tion 351(k)(4) of such Act (42 U.S.C. 262(k)(4)) 
16
and the system for assigning therapeutic equivalence 
17
ratings to drugs approved under section 505 of the 
18
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
19
355); 
20
(2) submit a report to the Congress on the re-
21
sults of the study under paragraph (1); and 
22
(3) update the list published under section 
23
351(k)(9)(A) of the Public Health Service Act (42 
24
U.S.C. 262(k)(9)(A)) (commonly referred to as the 
25
‘‘Purple Book’’) to implement such changes as the 
26
VerDate Sep 11 2014 
22:05 Sep 26, 2022
Jkt 029200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H8877.IH
H8877
kjohnson on DSK79L0C42PROD with BILLS
3 
•HR 8877 IH
Secretary deems necessary to harmonize the ap-
1
proach for communicating the substitutability of 
2
interchangeable biological products with the ap-
3
proach for communicating therapeutic equivalence 
4
ratings assigned to drugs, with the goals of— 
5
(A) minimizing impediments to the substi-
6
tution of interchangeable biological products; 
7
and 
8
(B) maintaining the distinct pathways by 
9
which biological products are licensed under 
10
section 351 of the Public Health Service Act 
11
(42 U.S.C. 262) and drugs are approved under 
12
section 505 of the Federal Food, Drug, and 
13
Cosmetic Act (21 U.S.C. 355). 
14
Æ 
VerDate Sep 11 2014 
22:05 Sep 26, 2022
Jkt 029200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H8877.IH
H8877
kjohnson on DSK79L0C42PROD with BILLS
